Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001213900-25-079145
Filing Date
2025-08-21
Accepted
2025-08-21 06:21:37
Documents
1
Period of Report
2025-08-18

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 3336
  Complete submission text file 0001213900-25-079145.txt   5091
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Issuer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2900 MCKINNON STREET SUITE 1101 DALLAS TX 75201
Business Address 2900 MCKINNON STREET SUITE 1101 DALLAS TX 75201 469-436-3669 EXT 501
B Group, Inc. (Reporting) CIK: 0002043476 (see all company filings)

State of Incorp.: KS | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38302 | Film No.: 251238313